Cancer
01 Jan 2013
Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to compare combination treatment of gemcitabine + oxaliplatin (GEMOX) with carboplatin + paclitaxel (CP) to determine if there is a difference in response and safety between the two drug combinations for the treatment of advanced non-small cell lung cancer (NSCLC). Official Title A Phase…
Cancer
01 Jan 2013
FASLODEX and AROMASIN in Hormone Receptor Positive Postmenopausal Women with Advanced Breast Cancer
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin (exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer. Patients will be treated until disease progression or until the investigator has determined that treatment is not in the best interest of the patient,…
Cancer
01 Jan 2013
Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known whether suppression of ovarian function plus either tamoxifen or exemestane is more effective than…
Cancer
01 Jan 2013
Pain Control in Patients With Recurrent or Metastatic Breast or Prostate Cancer
RATIONALE: An outpatient educational and behavioral skills training program may help patients with metastatic breast or prostate cancer live longer and more comfortably. PURPOSE: Randomizedpilot study to evaluate whether an outpatient educational and behavioral skills training program will improve pain control in patients who have metastatic or recurrent breast…
Cancer
01 Jan 2013
Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin’s Lymphoma
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known whether chemotherapy is…
Cancer
01 Jan 2013
Trial of PI-88 with Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)
PI-88 is a new experimental drug that inhibits tumour growth by reducing the formation of new blood vessels into tumours. Docetaxel is a standard second-line treatment offered to patients with non-small-cell lung cancer who haven’t responded to first-line therapies (platinum-based drugs or radiotherapy). Of this group of patients, only 20%…
Cancer
01 Jan 2013
Gemzar Prolongs Survival in Breast Cancer Trial
Eli Lilly and Co’s drug Gemzar should be more widely used to treat advanced breast cancer following a trial in which people taking it and the standard drug paclitaxel lived months longer than those taking paclitaxel alone, a researcher said on Saturday. Official Title Conditions Study Type Study Design Further…
Cancer
01 Jan 2013
The role of gemcitabine in the management of women with locally advanced and metastatic breast cancer
Prof Michael Friedlander Department of Medicine, Prince of Wales Clinical School, Randwick, NSW Cytotoxic chemotherapy plays an important role in the treatment of women with hormone-refractory or hormone-insensitive breast cancer. These agents have demonstrated benefits in providing symptom relief, temporarily reversing or delaying disease progression, and prolonging life1 with…
Cancer
01 Jan 2013
MabThera in aggressive non-Hodgkin’s lymphoma
Study of MabThera in aggressive non-Hodgkin’s lymphoma in patients less than 60 years old halted two years early due to significant efficacy benefits Official Title Conditions Study Type Study Design Further Details Study Start Eligibility & Criteria Total Enrolment Contact Details…
